Core Viewpoint - The announcement reveals that XinNuoWei plans to establish a joint venture with Zhongqi Pharmaceutical, focusing on the development and commercialization of innovative metabolic drugs, particularly targeting GLP-1 related products [1] Group 1: Joint Venture Details - XinNuoWei will invest 157.5 million yuan, holding a 35% stake in the joint venture, while Zhongqi Pharmaceutical will contribute 292.5 million yuan for a 65% stake [1] - The total investment for the joint venture is set at 450 million yuan [1] Group 2: Business Focus - The joint venture will primarily focus on the research, industrialization, and commercialization of innovative metabolic drugs, targeting areas such as overweight/obesity and type 2 diabetes [1] - The company plans to develop new drug formulations and expand indications continuously [1] Group 3: Product Pipeline - The joint venture will take over all GLP-1 related product pipelines from Shijiazhuang Pharmaceutical Group, including those in preclinical research, clinical stages, and those submitted for market approval [1] - The company aims to enhance its product matrix through various methods, including independent development, rights acquisition, and pipeline introduction [1]

Core Viewpoint - The company plans to establish a joint venture with Zhongqi Pharmaceutical Technology Co., Ltd. with a total investment of 450 million RMB, focusing on the development and commercialization of innovative metabolic drugs targeting GLP-1 [1] Group 1: Joint Venture Details - The company will contribute 157 million RMB, representing 35% of the registered capital [1] - Zhongqi Pharmaceutical will invest 292 million RMB, holding 65% of the registered capital [1] - The joint venture will primarily focus on the research, industrialization, and commercialization of innovative metabolic drugs [1] Group 2: Transaction Classification - This transaction is classified as a related party transaction and does not constitute a major asset reorganization [1]

Core Viewpoint - The establishment of a joint venture between XinNuoWei and Zhongqi Pharmaceutical aims to enhance the company's position in the innovative biopharmaceutical sector, particularly focusing on GLP-1 target products, driven by increasing health awareness and medical spending in China [1][2] Group 1 - The joint venture will be funded with a total investment of 45 million RMB, with XinNuoWei contributing 15.75 million RMB (35% ownership) and Zhongqi Pharmaceutical contributing 29.25 million RMB (65% ownership) [1] - The joint venture will focus on the research, industrialization, and commercialization of innovative metabolic drugs, particularly targeting obesity and type 2 diabetes [1] - The joint venture will take over all GLP-1 related product pipelines from Shiyao Group, including preclinical, clinical, and market application stages, and will explore various methods to expand its product pipeline [2]